Identification of a Primary Target of Thalidomide Teratogenicity
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Thalidomide Teratogenicity Target: In the late 1950s and early 1960s, thalidomide was prescribed to pregnant women as a cure for morning sickness, but it was then found to have developmental defects, most obviously, stunted limbs in thousands of babies. Although its use was banned worldwide, thalidomide has since been found to be a valuable treatment for a range of cancers, inflammatory disorders, and leprosy. Several hypotheses have been proposed, but the mechanism of action of thalidomide is unknown. Using zebrafish and chicken as animal models, Ito et al. (p. 1345 ) show that the protein cereblon is a primary target of thalidomide. Thalidomide exerts teratogenic effects by binding to cereblon and inhibiting associated enzymatic activity important for limb development. Knowing the mechanism of action of thalidomide should encourage the search for thalidomide derivatives without teratogenic activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IMiDs bind to cereblon and activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros family zinc finger proteins Ikaros (IKZF 1) and Aiolos (IKZF3).77–79”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [77]
In the citing paper
“Cereblon (CRBN), a substrate receptor for the cullin–RING ubiquitin ligase 4 (CRL4) complex, is a direct protein target for thalidomide teratogenicity and antitumor activity of immunomodulatory drugs (IMiDs).”
From Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon (2016) · cites this paper as Ito et al., 2010
In the citing paper
“FlagCRBN-W386E and FlagCRBN-W400E, and the double point mutant FlagCRBN-Y384A/W386A (FlagCRBN-YW/AA, which is defective in IMiD binding (Ito et al., 2010; Lopez-Girona et al., 2012)) failed to bind endogenous GS (Figure 6C).”
From Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon (2016) · cites this paper as Ito et al., 2010
In the citing paper
“The catastrophe was not a failure of pharmacokinetic scaling. Rather, the rodent species used for the original toxicology programs were largely resistant to thalidomide teratogenicity, while rabbits and primates are sensitive.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [55]
In the citing paper
“The case directly drove the development of ICH S5 reproductive toxicology guidelines mandating evaluation in two species, typically one rodent and one non-rodent, and underlies the broader principle that species panels for toxicodynamic endpoints must be selected on mechanistic grounds rather than convention [55,56].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [55]
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Effective targeted gene ‘knockdown’ in zebrafish
Nasevicius, A., & Ekker, S. C. (2000) · Nature Genetics · doi:10.1038/79951 · Cited by 2,483
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Sonic hedgehog mediates the polarizing activity of the ZPA
Riddle, R. D., Johnson, R. L., Laufer, E., & Tabin, C. (1993) · Cell · doi:10.1016/0092-8674(93)90626-2 · Cited by 2,307
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., & Kaplan, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1675 · Cited by 1,045
Groisman, R., Polanowska, J., Kuraoka, I., Sawada, J.-I., Saijo, M., Drapkin, R., Kisselev, A. F., Tanaka, K., & Nakatani, Y. (2003) · Cell · doi:10.1016/s0092-8674(03)00316-7 · Cited by 744
Back to the Future with Ubiquitin
Pickart, C. M. (2004) · Cell · doi:10.1016/s0092-8674(03)01074-2 · Cited by 697
Molecular architecture and assembly of the DDB1–CUL4A ubiquitin ligase machinery
Angers, S., Li, T., Yi, X., MacCoss, M. J., Moon, R. T., & Zheng, N. (2006) · Nature · doi:10.1038/nature05175 · Cited by 674
Jin, J., Arias, E. E., Chen, J., Harper, J. W., & Walter, J. C. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.08.010 · Cited by 632
Cited by
Items 101–200 of 1,003
Environmental factors influencing the risk of autism
Karimi, P., Kamali, E., Mousavi, S. M., & Karahmadi, M. (2017) · Journal of Research in Medical Sciences · doi:10.4103/1735-1995.200272 · Cited by 243
Hansen, J. D., Correa, M., Nagy, M. A., Alexander, M., Plantevin, V., Grant, V., Whitefield, B., Huang, D., Kercher, T., Harris, R., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01928 · Cited by 240
Hughes, S. J., & Ciulli, A. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170041 · Cited by 240
The fish embryo test (FET): origin, applications, and future
Braunbeck, T., Kais, B., Lammer, E., Otte, J., Schneider, K., Stengel, D., & Strecker, R. (2015) · Environmental Science and Pollution Research · doi:10.1007/s11356-014-3814-7 · Cited by 239
Prenatal factors associated with autism spectrum disorder (ASD)
Ornoy, A., Weinstein-Fudim, L., & Ergaz, Z. (2015) · Reproductive Toxicology · doi:10.1016/j.reprotox.2015.05.007 · Cited by 238
“Today, thalidomide is still used in the reatment of leprosy and multiple myeloma [118].”
BackgroundBulatov, E., & Ciulli, A. (2015) · Biochemical Journal · doi:10.1042/bj20141450 · Cited by 237
de Wispelaere, M., Du, G., Donovan, K. A., Zhang, T., Eleuteri, N. A., Yuan, J. C., Kalabathula, J., Nowak, R. P., Fischer, E. S., Gray, N. S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11429-w · Cited by 237
Ocio, E. M., Richardson, P. G., Rajkumar, S. V., Palumbo, A., Mateos, M. V., Orlowski, R., Kumar, S., Usmani, S., Roodman, D., Niesvizky, R., et al. (2014) · Leukemia · doi:10.1038/leu.2013.350 · Cited by 233
Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2
Mares, A., Miah, A. H., Smith, I. E. D., Rackham, M., Thawani, A. R., Cryan, J., Haile, P. A., Votta, B. J., Beal, A. M., Capriotti, C., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-0868-6 · Cited by 232
PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery
Gu, S., Cui, D., Chen, X., Xiong, X., & Zhao, Y. (2018) · BioEssays · doi:10.1002/bies.201700247 · Cited by 231
Recent Developments in PROTAC‐Mediated Protein Degradation: From Bench to Clinic
Hu, Z., & Crews, C. M. (2022) · ChemBioChem · doi:10.1002/cbic.202100270 · Cited by 231
Surka, C., Jin, L., Mbong, N., Lu, C.-C., Jang, I. S., Rychak, E., Mendy, D., Clayton, T., Tindall, E., Hsu, C., et al. (2021) · Blood · doi:10.1182/blood.2020008676 · Cited by 229
Bromodomains: Structure, function and pharmacology of inhibition
Ferri, E., Petosa, C., & McKenna, C. E. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.12.005 · Cited by 229
Multiple Myeloma: Available Therapies and Causes of Drug Resistance
Pinto, V., Bergantim, R., Caires, H. R., Seca, H., Guimarães, J. E., & Vasconcelos, M. H. (2020) · Cancers · doi:10.3390/cancers12020407 · Cited by 229
Targeted protein degradation via intramolecular bivalent glues
Hsia, O., Hinterndorfer, M., Cowan, A. D., Iso, K., Ishida, T., Sundaramoorthy, R., Nakasone, M. A., Imrichova, H., Schätz, C., Rukavina, A., et al. (2024) · Nature · doi:10.1038/s41586-024-07089-6 · Cited by 222
Bjorklund, C. C., Lu, L., Kang, J., Hagner, P. R., Havens, C. G., Amatangelo, M., Wang, M., Ren, Y., Couto, S., Breider, M., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.66 · Cited by 221
Bond, M. J., & Crews, C. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00011j · Cited by 221
Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15
Faust, T. B., Yoon, H., Nowak, R. P., Donovan, K. A., Li, Z., Cai, Q., Eleuteri, N. A., Zhang, T., Gray, N. S., & Fischer, E. S. (2020) · Nature Chemical Biology · doi:10.1038/s41589-019-0378-3 · Cited by 218
Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation
Lv, L., Chen, P., Cao, L., Li, Y., Zeng, Z., Cui, Y., Wu, Q., Li, J., Wang, J.-H., Dong, M.-Q., et al. (2020) · eLife · doi:10.7554/elife.59994 · Cited by 215
Chan, K.-H., Zengerle, M., Testa, A., & Ciulli, A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01912 · Cited by 215
Zhu, Y. X., Braggio, E., Shi, C.-X., Kortuem, K. M., Bruins, L. A., Schmidt, J. E., Chang, X.-B., Langlais, P., Luo, M., Jedlowski, P., et al. (2014) · Blood · doi:10.1182/blood-2014-02-557819 · Cited by 213
The novel mechanism of lenalidomide activity
Fink, E. C., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-07-567958 · Cited by 213
Cullin–RING ubiquitin E3 ligase regulation by the COP9 signalosome
Cavadini, S., Fischer, E. S., Bunker, R. D., Potenza, A., Lingaraju, G. M., Goldie, K. N., Mohamed, W. I., Faty, M., Petzold, G., Beckwith, R. E. J., et al. (2016) · Nature · doi:10.1038/nature17416 · Cited by 213
Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2018) · American Journal of Hematology · doi:10.1002/ajh.25117 · Cited by 209
Zebrafish (Danio rerio) embryos as a model for testing proteratogens
Weigt, S., Huebler, N., Strecker, R., Braunbeck, T., & Broschard, T. H. (2011) · Toxicology · doi:10.1016/j.tox.2011.01.004 · Cited by 209
The Ubiquitin–Proteasome System in Immune Cells
Çetin, G., Klafack, S., Studencka-Turski, M., Krüger, E., & Ebstein, F. (2021) · Biomolecules · doi:10.3390/biom11010060 · Cited by 209
Chirality and Surface Bonding Correlation in Atomically Precise Metal Nanoclusters
Li, Y., Higaki, T., Du, X., & Jin, R. (2020) · Advanced Materials · doi:10.1002/adma.201905488 · Cited by 209
Multiple myeloma: 2014 Update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2014) · American Journal of Hematology · doi:10.1002/ajh.23810 · Cited by 208
Targeted Protein Degradation by Small Molecules
Bondeson, D. P., & Crews, C. M. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103507 · Cited by 207
“Importantly, mutations in cereblon that block thalidomide binding also inhibit models of thalidomide teratogenicity in chicken and zebrafish (28).”
BackgroundStructural regulation of cullin-RING ubiquitin ligase complexes
Duda, D. M., Scott, D. C., Calabrese, M. F., Zimmerman, E. S., Zheng, N., & Schulman, B. A. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2011.01.003 · Cited by 205
Emerging New Concepts of Degrader Technologies
Ding, Y., Fei, Y., & Lu, B. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.04.005 · Cited by 204
“CRBNwas initially identified as the primary mediator of the teratogenic activity of thalidomide by Handa and colleagues [26].”
BackgroundThe Chemical Biology of Reversible Lysine Post-translational Modifications
Wang, Z. A., & Cole, P. A. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.07.002 · Cited by 201
Selderslaghs, I. W. T., Blust, R., & Witters, H. E. (2012) · Reproductive Toxicology · doi:10.1016/j.reprotox.2011.08.003 · Cited by 201
Chasing molecular glue degraders: screening approaches
Domostegui, A., Nieto-Barrado, L., Perez-Lopez, C., & Mayor-Ruiz, C. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00197g · Cited by 200
Unifying principles of bifunctional, proximity-inducing small molecules
Gerry, C. J., & Schreiber, S. L. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0469-1 · Cited by 199
In Silico Modeling of PROTAC-Mediated Ternary Complexes: Validation and Application
Drummond, M. L., & Williams, C. I. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00872 · Cited by 199
Proximity-Based Modalities for Biology and Medicine
Liu, X., & Ciulli, A. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00395 · Cited by 196
The E3 ligase adapter cereblon targets the C-terminal cyclic imide degron
Ichikawa, S., Flaxman, H. A., Xu, W., Vallavoju, N., Lloyd, H. C., Wang, B., Shen, D., Pratt, M. R., & Woo, C. M. (2022) · Nature · doi:10.1038/s41586-022-05333-5 · Cited by 195
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy
Galluzzi, L., Vacchelli, E., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.20696 · Cited by 195
NF-κB: master regulator of cellular responses in health and disease
Hoffmann, A., Cheng, G., & Baltimore, D. (2025) · Immunity & Inflammation · doi:10.1007/s44466-025-00014-0 · Cited by 193
The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development
Rehman, W., Arfons, L. M., & Lazarus, H. M. (2011) · Therapeutic Advances in Hematology · doi:10.1177/2040620711413165 · Cited by 192
Yang, J., Li, Y., Aguilar, A., Liu, Z., Yang, C.-Y., & Wang, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00846 · Cited by 190
Development of the first small molecule histone deacetylase 6 (HDAC6) degraders
Yang, K., Song, Y., Xie, H., Wu, H., Wu, Y.-T., Leisten, E. D., & Tang, W. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.05.057 · Cited by 190
Prey for the Proteasome: Targeted Protein Degradation—A Medicinal Chemist's Perspective
Luh, L. M., Scheib, U., Juenemann, K., Wortmann, L., Brands, M., & Cromm, P. M. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202004310 · Cited by 189
Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors
Romero, F. A., Taylor, A. M., Crawford, T. D., Tsui, V., Côté, A., & Magnuson, S. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01514 · Cited by 188
Molecular glues for protein-protein interactions: Progressing toward a new dream
Konstantinidou, M., & Arkin, M. R. (2024) · Cell Chemical Biology · doi:10.1016/j.chembiol.2024.04.002 · Cited by 187
PROTACs: A novel strategy for cancer therapy
Liu, J., Ma, J., Liu, Y., Xia, J., Li, Y., Wang, Z. P., & Wei, W. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.006 · Cited by 186
Harnessing the Power of Proteolysis for Targeted Protein Inactivation
Verma, R., Mohl, D., & Deshaies, R. J. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.01.010 · Cited by 185
Rational Chemical Design of Molecular Glue Degraders
Toriki, E. S., Papatzimas, J. W., Nishikawa, K., Dovala, D., Frank, A. O., Hesse, M. J., Dankova, D., Song, J.-G., Bruce-Smythe, M., Struble, H., et al. (2023) · ACS Central Science · doi:10.1021/acscentsci.2c01317 · Cited by 184
Target deconvolution techniques in modern phenotypic profiling
Lee, J., & Bogyo, M. S. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2012.12.022 · Cited by 184
Eichner, R., Heider, M., Fernández-Sáiz, V., van Bebber, F., Garz, A.-K., Lemeer, S., Rudelius, M., Targosz, B.-S., Jacobs, L., Knorn, A.-M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4128 · Cited by 183
Teratogenic effects of thalidomide: molecular mechanisms
Ito, T., Ando, H., & Handa, H. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0619-9 · Cited by 182
Self-citationDu, X., Volkov, O. A., Czerwinski, R. M., Tan, H., Huerta, C., Morton, E. R., Rizzi, J. P., Wehn, P. M., Xu, R., Nijhawan, D., et al. (2019) · Structure · doi:10.1016/j.str.2019.10.005 · Cited by 181
Targeted protein degradation as a powerful research tool in basic biology and drug target discovery
Wu, T., Yoon, H., Xiong, Y., Dixon-Clarke, S. E., Nowak, R. P., & Fischer, E. S. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0438-0 · Cited by 180
Trial Watch: Toll-like receptor agonists for cancer therapy
Vacchelli, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.25238 · Cited by 154
Genome-wide localization of small molecules
Anders, L., Guenther, M. G., Qi, J., Fan, Z. P., Marineau, J. J., Rahl, P. B., Lovén, J., Sigova, A. A., Smith, W. B., Lee, T. I., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2776 · Cited by 179
Systematic approaches to identify E3 ligase substrates
Iconomou, M., & Saunders, D. N. (2016) · Biochemical Journal · doi:10.1042/bcj20160719 · Cited by 178
Environmental risk factors for autism
Dietert, R. R., Dietert, J. M., & Dewitt, J. C. (2011) · Emerging Health Threats Journal · doi:10.3402/ehtj.v4i0.7111 · Cited by 135
Van Nguyen, T., Lee, J. E., Sweredoski, M. J., Yang, S.-J., Jeon, S.-J., Harrison, J. S., Yim, J.-H., Lee, S. G., Handa, H., Kuhlman, B., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.02.032 · Cited by 177
“FlagCRBN-W386E and FlagCRBNW400E, and the double point mutant FlagCRBN-Y384A/W386A (FlagCRBN-YW/AA, which is defective in IMiD binding (Ito et al., 2010; Lopez-Girona et al., 2012)) failed to”
InfluentialSelf-citationIshoey, M., Chorn, S., Singh, N., Jaeger, M. G., Brand, M., Paulk, J., Bauer, S., Erb, M. A., Parapatics, K., Müller, A. C., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b00969 · Cited by 177
Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders
Bauer, D. E., Kamran, S. C., & Orkin, S. H. (2012) · Blood · doi:10.1182/blood-2012-06-292078 · Cited by 177
Environmental Risk Factors for Congenital Heart Disease
Kalisch-Smith, J. I., Ved, N., & Sparrow, D. B. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a037234 · Cited by 177
pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase
An, J., Ponthier, C. M., Sack, R., Seebacher, J., Stadler, M. B., Donovan, K. A., & Fischer, E. S. (2017) · Nature Communications · doi:10.1038/ncomms15398 · Cited by 176
Gooding, S., Ansari-Pour, N., Towfic, F., Ortiz Estévez, M., Chamberlain, P. P., Tsai, K.-T., Flynt, E., Hirst, M., Rozelle, D., Dhiman, P., et al. (2021) · Blood · doi:10.1182/blood.2020007081 · Cited by 172
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms
Abdi, J., Chen, G., & Chang, H. (2013) · Oncotarget · doi:10.18632/oncotarget.1497 · Cited by 172
Trial watch: Peptide vaccines in cancer therapy
Vacchelli, E., Martins, I., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2012) · OncoImmunology · doi:10.4161/onci.22428 · Cited by 171
Haven't got a glue: Protein surface variation for the design of molecular glue degraders
Kozicka, Z., & Thomä, N. H. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.009 · Cited by 170
Emerging degrader technologies engaging lysosomal pathways
Ding, Y., Xing, D., Fei, Y., & Lu, B. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00624c · Cited by 170
Bruton tyrosine kinase degradation as a therapeutic strategy for cancer
Dobrovolsky, D., Wang, E. S., Morrow, S., Leahy, C., Faust, T., Nowak, R. P., Donovan, K. A., Yang, G., Li, Z., Fischer, E. S., et al. (2019) · Blood · doi:10.1182/blood-2018-07-862953 · Cited by 169
Jeong, H., Choi, E., Ellis, E., & Lee, T. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb00557a · Cited by 169
Buckley, D. L., & Crews, C. M. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307761 · Cited by 153
Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy
Bonazzi, S., d’Hennezel, E., Beckwith, R. E. J., Xu, L., Fazal, A., Magracheva, A., Ramesh, R., Cernijenko, A., Antonakos, B., Bhang, H.-E. C., et al. (2023) · Cell Chemical Biology · doi:10.1016/j.chembiol.2023.02.005 · Cited by 167
Fetal exposure to teratogens: Evidence of genes involved in autism
Dufour-Rainfray, D., Vourc’h, P., Tourlet, S., Guilloteau, D., Chalon, S., & Andres, C. R. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.12.013 · Cited by 167
Zhang, L., Kosek, J., Wang, M., Heise, C., Schafer, P. H., & Chopra, R. (2013) · British Journal of Haematology · doi:10.1111/bjh.12172 · Cited by 167
An E3 ligase guide to the galaxy of small-molecule-induced protein degradation
Jevtić, P., Haakonsen, D. L., & Rapé, M. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.002 · Cited by 143
Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back
Bianchi, G., & Anderson, K. C. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21252 · Cited by 131
From Discovery to Bedside: Targeting the Ubiquitin System
Wertz, I. E., & Wang, X. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.10.022 · Cited by 166
Chiral plasmonic nanostructures: recent advances in their synthesis and applications
Wu, W., & Pauly, M. (2022) · Materials Advances · doi:10.1039/d1ma00915j · Cited by 166
Tokunaga, E., Yamamoto, T., Ito, E., & Shibata, N. (2018) · Scientific Reports · doi:10.1038/s41598-018-35457-6 · Cited by 165
Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma
Barwick, B. G., Gupta, V. A., Vertino, P. M., & Boise, L. H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01121 · Cited by 163
E3 ligase ligand chemistries: from building blocks to protein degraders
Sosič, I., Bricelj, A., & Steinebach, C. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00148a · Cited by 163
PROTACs– a game-changing technology
Konstantinidou, M., Li, J., Zhang, B., Wang, Z., Shaabani, S., Ter Brake, F., Essa, K., & Dömling, A. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1659242 · Cited by 163
AirID, a novel proximity biotinylation enzyme, for analysis of protein–protein interactions
Kido, K., Yamanaka, S., Nakano, S., Motani, K., Shinohara, S., Nozawa, A., Kosako, H., Ito, S., & Sawasaki, T. (2020) · eLife · doi:10.7554/elife.54983 · Cited by 163
Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation
Kannt, A., & Đikić, I. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.007 · Cited by 142
Deshaies, R. J. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1887 · Cited by 162
PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery
Guedeney, N., Cornu, M., Schwalen, F., Kieffer, C., & Voisin-Chiret, A. S. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103395 · Cited by 162
Homo-PROTACs for the Chemical Knockdown of Cereblon
Steinebach, C., Lindner, S., Udeshi, N. D., Mani, D. C., Kehm, H., Köpff, S., Carr, S. A., Gütschow, M., & Krönke, J. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00693 · Cited by 155
Targeted protein degradation: current and future challenges
Hanzl, A., & Winter, G. E. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.11.012 · Cited by 149
Von Hippel–Lindau disease: insights into oxygen sensing, protein degradation, and cancer
Kaelin, W. G. (2022) · Journal of Clinical Investigation · doi:10.1172/jci162480 · Cited by 161
Targeting Brd4 for cancer therapy: inhibitors and degraders
Duan, Y., Guan, Y., Qin, W., Zhai, X., Yu, B., & Liu, H. (2018) · MedChemComm · doi:10.1039/c8md00198g · Cited by 161
Strategies for Targeting the NLRP3 Inflammasome in the Clinical and Preclinical Space
Schwaid, A. G., & Spencer, K. B. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01307 · Cited by 160
DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
Li, F., Hu, Q., Zhang, X., Sun, R., Liu, Z., Wu, S., Tian, S., Ma, X., Dai, Z., Yang, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34807-3 · Cited by 159
Hansen, J. D., Correa, M., Alexander, M., Nagy, M., Huang, D., Sapienza, J., Lu, G., LeBrun, L. A., Cathers, B. E., Zhang, W., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01489 · Cited by 159
Phenyl‐Glutarimides: Alternative Cereblon Binders for the Design of PROTACs
Min, J., Mayasundari, A., Keramatnia, F., Jonchere, B., Yang, S. W., Jarusiewicz, J., Actis, M., Das, S., Young, B., Slavish, J., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202108848 · Cited by 159
Multiple myeloma: 2013 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2013) · American Journal of Hematology · doi:10.1002/ajh.23390 · Cited by 159
Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
Chanan-Khan, A. A., Swaika, A., Paulus, A., Kumar, S. K., Mikhael, J. R., Rajkumar, S. V., Dispenzieri, A., & Lacy, M. Q. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.38 · Cited by 144
A history of the roles of cytochrome P450 enzymes in the toxicity of drugs
Guengerich, F. P. (2020) · Toxicological Research · doi:10.1007/s43188-020-00056-z · Cited by 159
Yamamoto, J., Ito, T., Yamaguchi, Y., & Handa, H. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00116k · Cited by 158
Self-citationQuantifying Ubiquitin Signaling
Ordureau, A., Münch, C., & Harper, J. W. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.02.020 · Cited by 149
Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta
Bai, N., Miller, S. A., Andrianov, G. V., Yates, M., Kirubakaran, P., & Karanicolas, J. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01451 · Cited by 157
Metadata
- Authors
- Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H.
- Affiliations
- Tokyo Institute of Technology (JP)
- Tohoku University (JP)
- Astellas Pharma (Japan) (JP)
- Corresponding author
- Ito, Takumi
- Ando, Hideki
- Handa, Hiroshi
- Venue
- Science
- Published
- 2010-03-12
- Volume
- 327
- Issue
- 5971
- Pages
- 1345-1350
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1997952190
- Cited by
- 2,136
- References
- 36
- Citations by year
- 2026: 141 · 2025: 189 · 2024: 189 · 2023: 174 · 2022: 179 · 2021: 169 · 2020: 171 · 2019: 120 · 2018: 126 · 2017: 104 · 2016: 100 · 2015: 114 · 2014: 99 · 2013: 103 · 2012: 67
- FWCI
- 74.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Developmental Biology › Congenital limb and hand anomalies
- Keywords
- thalidomide, teratogenicity, cereblon, E3 ubiquitin ligase, DDB1, CUL4A, limb malformations, FGF8, limb outgrowth, ubiquitination, zebrafish, chick embryo, drug repurposing
- MeSH terms
- Animals, Carrier Proteins, Chick Embryo, DNA-Binding Proteins, Embryo, Nonmammalian, Fibroblast Growth Factors, Forelimb, HeLa Cells, Humans, Peptide Hydrolases, Teratogens, Thalidomide, Zebrafish, Gene Expression Regulation, Developmental, Zebrafish Proteins, Ubiquitin-Protein Ligases, Cullin Proteins, Embryonic Development, Adaptor Proteins, Signal Transducing, Mutant Proteins, Ubiquitination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.